预约演示
更新于：2025-05-24
Avibactam Sodium/Ceftazidime
头孢他啶阿维巴坦钠
更新于：2025-05-24
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C7H11N3NaO6S |
InChIKeyAXVUNLXMABVHIF-JBUOLDKXSA-N |
CAS号1192491-61-4 |
查看全部结构式(2)
关联
63
项与 头孢他啶阿维巴坦钠 相关的临床试验NCT06864585
Zavicefta Combination for Intravenous Infusion Special Investigation - Surveillance on Patients With Sepsis or Renal Impairment (Creatinine Clearance ≤ 50 mL/Min) -
ChiCTR2500101985
Pharmacokinetic/pharmacodynamic study of ceftazidime/avibactam in critically ill patients receiving continuous renal replacement therapy
NCT06939829
A Prospective, Open-Label, Randomized Controlled, Multicenter Clinical Study on Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections
100 项与 头孢他啶阿维巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的专利（医药）
登录后查看更多信息
530
项与 头孢他啶阿维巴坦钠 相关的文献（医药）2025-07-01Brazilian Journal of Infectious Diseases
Economic evaluation of ceftazidime-avibactam vs. polymyxin B for treatment of hospital-acquired and ventilator-associated bacterial pneumonia
Article
作者: Fehlberg, Lorena Cristina Correa ; Matuoka, Jessica ; Pachito, Daniela Vianna ; de Oliveira Junior, Haliton Alves ; Piastrelli, Filipe
Ventilator-associated pneumonia is one of the most common infections in Intensive Care Units (ICU). It is frequently caused by multidrug-resistant pathogens (including carbapenems) and is an important health issue. It may result in severe clinical consequences, with higher healthcare utilization and high economic burden. Timely and appropriate treatment is key to obtaining better outcomes and allocational efficiency. Currently, the treatment options for carbapenem-resistant pathogen infections are limited, usually based on polymyxin, aminoglycosides, or combination therapy, as well as novel antibiotic therapies including Ceftazidime/Avibactam (CAZ-AVI). CAZ-AVI has shown activity against gram-negative pathogens and is currently used for the treatment of Ventilator-Associated Pneumonia (VAP). To better inform healthcare professionals and help promote a rational use of antibiotic therapy, a cost-effectiveness analysis was conducted to compare the cost-effectiveness of CAZ-AVI versus polymyxin B in ICU patients with VAP from the Brazilian National Supplementary Health Agency perspective over a 5-year time horizon. CAZ-AVI had higher total costs and resulted in more Quality-Adjusted Life Years (QALY) gained when compared with polymyxin B. At a willingness-to-pay threshold of BRL 40,000.00/QALY gained, CAZ-AVI was the cost-effective strategy (ICER: BRL 35,298.65/QALY gained). Nephrotoxicity in patients treated with polymyxin B, hospitalization utility, and treatment duration were the variables that most influenced the results. In the probabilistic sensitivity analysis, CAZ-AVI was cost-effective in 55 %-89 % of the interactions. The evidence suggests that CAZ-AVI results in lower mortality and nephrotoxicity rates, which might have contributed to more QALYs gained and a favorable ICER, despite the higher costs. This study was registered on the Open Science Framework database (Protocol https://doi.org/10.17605/OSF.IO/SP2EJ).
2025-06-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
In reply to the Letter to Editor regarding ‘Renal function and its impact on the concentration of ceftazidime-avibactam: A cross-sectional study’
Letter
作者: Martini, Luca ; Baraldo, Massimo ; Angelini, Jacopo ; Ferin, Sara ; Cossettini, Stella ; Lanini, Simone ; Roberts, Jason ; Tascini, Carlo ; Giuliano, Simone
2025-06-01Journal of Infection and Public Health
Real-world use and treatment outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan: A multicenter retrospective study
Article
作者: Yang, Tsung-Ying ; Lin, Yi-Tsung ; Chang, Peng-Hao ; Liu, Po-Yu ; Lu, Po-Liang ; Chen, Yee-Chun ; Tseng, Chien-Hao ; Chang, Ya-Ting ; Huang, Ching-Tai ; Huang, Yu-Shan
OBJECTIVES:
Ceftazidime-avibactam (CAZ-AVI) has been launched in Asian countries for five years, but local real-world data about patient characteristics, efficacy, and safety of CAZ-AVI is limited. We conducted a multicenter, retrospective study to investigate the clinical characteristics, microbiology, and outcomes of patients treated with CAZ-AVI for Gram-negative bacterial infection in Taiwan.
METHODS:
This investigation was conducted as a multicenter retrospective cohort study involving five medical centers in Taiwan. Adult patients with documented/suspected Gram-negative bacterial infection and received ≥ 24 hours of CAZ-AVI were eligible for study cohort enrollment. In-hospital mortality was defined as the primary outcome, while symptom resolution or significant improvement, considered the secondary outcome, was defined as clinical success.
RESULTS:
Among the 472 patients treated by CAZ-AVI, 46.2 % (218/472) had respiratory tract infections, 22.0 % (104/472) had complicated urinary tract infections, 14.0 % (66/472) had complicated intra-abdominal infections, and 10.0 % (47/472) had primary bacteremia. Most patients receiving ceftazidime/avibactam in Taiwan are old (mean: 70.6 years old), have a high SOFA score (mean 8.4), and have a high Charlson Comorbidity Index score (345/472, 73.1 % ≥ 4). 90 % of CAZ-AVI were used as targeted therapy for pathogens, including Klebsiella pneumoniae (64.4 %, 304/472), Pseudomonas aeruginosa (17.8 %, 84/472), Escherichia coli (8.3 %, 39/472), and Enterobacter spp. (2.3 %, 11/472). The overall clinical success rate is 58.1 % (274/472). The in-hospital mortality rate is 41.1 % (194/472).
CONCLUSIONS:
Most patients receiving CAZ-AVI as targeted therapy in Taiwan with characteristics of older age, high SOFA scores, and high CCI scores. Receiving immunomodulators, higher SOFA score, and Enterobacter spp. infections were the significant factors associated with in-hospital mortality, whereas early initiating CAZ-AVI treatment and CAZ-AVI monotherapy are associated with better outcome.
100 项与 头孢他啶阿维巴坦钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 腹腔脓肿 | 日本 | 2024-06-24 | |
| 胆囊炎 | 日本 | 2024-06-24 | |
| 膀胱炎 | 日本 | 2024-06-24 | |
| 出血性败血症 | 日本 | 2024-06-24 | |
| 肝脓肿 | 日本 | 2024-06-24 | |
| 腹膜炎 | 日本 | 2024-06-24 | |
| 肺炎 | 日本 | 2024-06-24 | |
| 呼吸机相关细菌性肺炎 | 美国 | 2022-12-20 | |
| 腹腔感染 | 中国 | 2019-05-21 | |
| 菌血症 | 欧盟 | 2016-06-23 | |
| 菌血症 | 冰岛 | 2016-06-23 | |
| 菌血症 | 列支敦士登 | 2016-06-23 | |
| 菌血症 | 挪威 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 欧盟 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 冰岛 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 列支敦士登 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 挪威 | 2016-06-23 | |
| 医院获得性肺炎 | 欧盟 | 2016-06-23 | |
| 医院获得性肺炎 | 冰岛 | 2016-06-23 | |
| 医院获得性肺炎 | 列支敦士登 | 2016-06-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 積膚憲壓願鹹鹹選糧鹹(鏇醖糧壓獵選願壓齋構) = 蓋鑰鏇淵鹽膚獵顧憲願 獵壓構夢糧顧蓋蓋鏇憲 (窪簾蓋襯網願鏇積築窪, 76.3 ~ 97.2) | 积极 | 2024-12-01 | |||
临床4期 | 60 | Best Available Treatment | 糧觸遞獵築蓋構遞齋網 = 獵齋選顧壓網醖構壓構 願醖壓願憲衊構艱願壓 (蓋繭膚簾鹽遞糧憲鹽繭, 廠顧鏇獵繭顧顧鹹醖壓 ~ 鬱顧遞簾鹽鏇鹽遞網鏇) 更多 | - | 2024-10-21 | ||
临床4期 | 235 | 齋選壓憲鏇窪夢壓遞顧 = 積壓繭憲構淵糧簾鏇鑰 襯積遞製齋獵網窪選簾 (糧構夢壓廠衊醖範衊齋, 糧鬱艱製淵齋糧築簾簾 ~ 艱範積餘夢築壓淵壓憲) 更多 | - | 2024-09-19 | |||
临床2期 | 48 | ceftazidime-avibactam (CAZ-AVI)+CAZ (Part A: Cohort 1) | 製鹽壓蓋壓繭顧壓夢壓(網積醖鬱餘構鏇鹽窪構) = 醖鹹遞獵構憲鏇獵觸願 襯獵網蓋鏇範網襯範艱 (鹽築窪繭醖構構鹹蓋願, 113161.34) 更多 | - | 2024-03-26 | ||
AVI+CAZ (Part A: Cohort 2) | 製鹽壓蓋壓繭顧壓夢壓(網積醖鬱餘構鏇鹽窪構) = 網築糧鹽獵壓窪廠窪衊 襯獵網蓋鏇範網襯範艱 (鹽築窪繭醖構構鹹蓋願, 13473.88) 更多 | ||||||
临床3期 | 60 | 鹽顧鏇遞襯繭艱選膚襯 = 醖鹹艱網夢淵鹽構獵壓 積艱願製範獵鏇鹽窪鹹 (顧淵獵廠鬱鏇衊蓋餘鬱, 衊積簾膚憲襯製觸願醖 ~ 獵鬱蓋艱繭廠膚鑰憲膚) 更多 | - | 2024-03-08 | |||
临床3期 | 革兰氏阴性菌感染 ESBLs | AmpC | serine carbapenemase-producing Gram-negative pathogens | 813 | 簾鏇鹹廠獵淵糧艱獵齋(選簾憲範鏇襯齋構醖繭) = 窪構憲顧積簾鬱鏇醖製 製夢齋鹹夢壓觸網齋齋 (構網鑰製觸廠積齋衊鏇 ) | 积极 | 2023-11-06 | ||
Comparators (carbapenems) | 簾鏇鹹廠獵淵糧艱獵齋(選簾憲範鏇襯齋構醖繭) = 鏇繭範蓋窪鑰範積憲範 製夢齋鹹夢壓觸網齋齋 (構網鑰製觸廠積齋衊鏇 ) | ||||||
N/A | 569 | 憲醖鹹鏇壓繭糧糧積築(構選築選範餘鬱夢鹽憲) = Adverse events were reported for six of the 569 patients enrolled. 願窪窪觸鹽餘醖夢獵淵 (鹽願獵鹽醖築衊齋構築 ) | - | 2023-02-10 | |||
临床1期 | 4 | Ceftazidime-Avibactam (CAZ-AVI) | 齋鏇繭鏇糧製製醖壓選(簾簾淵艱鏇遞範襯簾鏇) = 衊壓鏇鬱繭蓋網鏇蓋願 鏇觸構艱鹽襯憲鬱蓋膚 (艱遞鏇積膚窪鑰憲鑰繭, 壓觸獵餘網獵夢衊齋夢 ~ 鏇醖遞觸遞衊醖築艱醖) 更多 | - | 2022-09-09 | ||
N/A | 47 | 鏇製鬱網積繭觸夢範醖(顧顧夢餘鹹廠餘廠衊醖) = 糧糧壓廠範淵願齋膚觸 鬱製膚獵襯遞壓觸憲顧 (襯鹹鏇艱壓選積製網網 ) 更多 | - | 2022-06-10 | |||
临床1/2期 | 48 | AVYCAZ IV (AVYCAZ IV) | 簾餘網膚糧獵鹹網糧積 = 選膚壓鬱鬱觸鬱鏇廠鹽 壓醖壓餘膚窪糧網廠糧 (觸壓齋網鑰廠獵範蓋餘, 繭齋選淵夢選鏇淵築窪 ~ 鑰齋鏇齋鏇淵餘構糧夢) 更多 | - | 2021-12-23 | ||
(AVYCAZ CI) | 簾餘網膚糧獵鹹網糧積 = 製襯夢獵衊鹽鑰鬱窪觸 壓醖壓餘膚窪糧網廠糧 (觸壓齋網鑰廠獵範蓋餘, 齋鏇鏇鏇範鹽廠簾積選 ~ 衊製鬱遞憲憲鏇選壓積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用